Related Experiment Video
Updated: Jul 3, 2026
08:12
High-throughput Screening for Protein-based Inheritance in S. cerevisiae
Published on: August 8, 2017
Novel dominant-negative prion protein mutants identified from a randomized library
David Ott1, Cornelia Taraborrelli, Adriano Aguzzi
1Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland.
Protein Engineering, Design & Selection : PEDS
|August 5, 2008
Summary
Researchers identified novel dominant-negative mutants (DNMs) that inhibit prion replication in cells, offering potential new treatments for untreatable prion diseases. These DNMs effectively antagonize PrP(Sc) propagation, even with lower cell surface display.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Prion diseases are fatal neurodegenerative disorders.
- Characterized by the accumulation of misfolded prion protein (PrPSc).
- Current treatments are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify novel dominant-negative mutants (DNMs) of the cellular prion protein (PrPC).
- To evaluate the efficacy of these DNMs in inhibiting prion replication.
- To explore the role of cell surface display in DNM activity.
Main Methods:
- Generated a library of PrPC variants with random mutations in the helix-3 domain.
- Screened for DNMs that inhibit prion (Rocky Mountain Laboratory strain) replication in infected N2a cells.
- Assessed cell surface display levels of identified DNMs.
Main Results:
- Identified novel DNMs, S221P and Y217C, that efficiently antagonize PrPSc propagation.
- Validated known DNMs (Q167R, Q218K) confirming the screening approach's effectiveness.
- Found that robust cell surface display is not essential for potent prion antagonism.
Conclusions:
- Novel DNMs offer promising therapeutic avenues for prion diseases.
- These DNMs can effectively inhibit PrPSc propagation.
- The findings suggest new strategies for developing targeted prion disease therapeutics.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
02:27Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...